Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305069 | 0.81 | LMNA (0.33) | LMNAALDH1A1TYMP | |
| SCHEMBL17703490 | 0.81 | LMNA (0.33) | LMNAALDH1A1TYMP | |
| SCHEMBL21056824 | 0.79 | ALDH1A1 (0.38) | LMNAALDH1A1TYMP | |
| SCHEMBL17823732 | 0.79 | ALDH1A1 (0.38) | LMNAALDH1A1TYMP | |
| SCHEMBL13745674 | 0.79 | GAA (0.38) | LMNAALDH1A1TYMP | |
| SCHEMBL17823959 | 0.79 | ALDH1A1 (0.38) | LMNAALDH1A1TYMP | |
| SCHEMBL11345701 | 0.79 | GAA (0.38) | LMNAALDH1A1TYMP | |
| SCHEMBL14149338 | 0.79 | LMNA (0.41) | LMNA | |
| SCHEMBL8745038 | 0.78 | TDP1 (0.47) | LMNA | |
| SCHEMBL12323568 | 0.78 | LMNA (0.34) | LMNAALDH1A1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-20150232418-A1 | HYDROXY-SUBSTITUTED AMINO AND AMMONIUM DERIVATIVES AND THEIR MEDICAL USE | GLYCOREGIMMUNE, INC. (US) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232418-A1 | HYDROXY-SUBSTITUTED AMINO AND AMMONIUM DERIVATIVES AND THEIR MEDICAL USE | PAH, AADAT, HRH3 | LMNA 3911/4885ALDH1A1 542/4885TYMP 962/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | LMNA 2135/4885ALDH1A1 999/4885TYMP 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.